$167 Trillion and Counting: New Report Finds America's Investment in Innovation Pays Dividends. MFN Policy Puts it at Risk

A groundbreaking report quantifies what patients and their families have long understood: American medical innovation is making life better for all of us.

This new analysis, conducted by researchers at the University of Chicago and supported by the U.S. Chamber of Commerce, estimates medical breakthroughs delivered $167.5 trillion in societal value to the United States.

How Innovation Delivers

The researchers looked at innovations in four major disease areas – HIV, heart disease, breast cancer, and obesity – and measured the impact on aggregate health gains, productivity, changes in healthcare spending, and federal tax revenues.

Altogether, these innovations produced an average of $5.6 trillion in annual value for the U.S. over a 30-year horizon. That’s over $16,000 in value per person, per year.

Here’s how these innovations have transformed countless lives: In 1995, an HIV diagnosis meant certain death; patients had roughly two years to live. Today, thanks to American innovation, HIV patients live full lifespans. Breast cancer survivors live seven more years on average. Advances in heart disease treatments have prevented countless heart attacks and added critical years to patients’ lives during their prime working age. And while still in early stages, innovations in obesity treatments are estimated to add nearly a year of life for millions of Americans. 

Beyond the human dimension, the economic ripple effect from these innovations is enormous. Healthier workers remained in the labor force longer, adding $10.8 trillion to the economy in the form of increased productivity. Federal coffers benefitted from $2 trillion in additional tax revenue as Americans stayed healthier employed and more productive throughout their lives.

A Critical Choice for Policymakers

But this success story is under threat. Policymakers are seriously considering most favored nation, a policy that would tie American drug prices to those set by foreign governments with far less innovation capacity. The U.S. Chamber warns this proposal could lead to an 18.5% collapse in R&D spending, 75% fewer clinical trials and the loss of 2.2 million high-skilled jobs across the country. 

That’s fewer medicines, delayed access and broken promises to patients waiting for next-generation cures.

The timing is particularly critical as China pursues an aggressive strategy to achieve global biomedical dominance. While Beijing pours billions into clinical infrastructure and manufacturing, America would be dismantling the very incentives that have made it the world leader in innovation. 

U.S. policymakers have a clear choice: Protect the system that has delivered extraordinary returns for patients and the economy or adopt policies that have already failed in Europe, in turn handing China a decisive advantage.

The data speaks for itself. Innovation-friendly policies work. Now, Congress must act to preserve them.